BIOC Quote, Trading Chart, Biocept Inc.
home / stock / bioc / bioc quote
$4.57 Last:
-0.87% Change Percent:
$4.59 Open:
$4.57 Previous Close:
$4.65 High:
$4.4972 Low:
146,284 Volume:
06/14/2021 04:42:33 am Last Trade Date Time:
Quotes are delayed by 15 to 20 minutes.
BIOC Last Five Trading Days
| Stock Date | Open Price | Close Price | High | Low | Volume |
|---|---|---|---|---|---|
| 2021-06-14 | 4.59 | 4.57 | 4.65 | 4.4972 | 146,284 |
| 2021-06-11 | 4.62 | 4.61 | 4.65 | 4.5 | 146,880 |
| 2021-06-10 | 4.8 | 4.52 | 4.825 | 4.49 | 250,221 |
| 2021-06-09 | 4.705 | 4.8 | 4.85 | 4.6 | 462,561 |
| 2021-06-08 | 4.54 | 4.52 | 4.5788 | 4.455 | 152,261 |
| 2021-06-07 | 4.31 | 4.46 | 4.515 | 4.31 | 192,109 |
| 2021-06-04 | 4.33 | 4.34 | 4.3643 | 4.28 | 121,517 |
| 2021-06-03 | 4.41 | 4.28 | 4.43 | 4.2 | 229,969 |
| 2021-06-02 | 4.36 | 4.39 | 4.44 | 4.3 | 171,445 |
| 2021-06-01 | 4.5 | 4.38 | 4.5 | 4.33 | 142,262 |
| 2021-05-31 | 4.63 | 4.52 | 4.69 | 4.5 | 99,159 |
| 2021-05-28 | 4.63 | 4.52 | 4.69 | 4.5 | 98,366 |
| 2021-05-27 | 4.61 | 4.6 | 4.69 | 4.56 | 117,655 |
| 2021-05-26 | 4.45 | 4.59 | 4.59 | 4.4344 | 116,111 |
| 2021-05-25 | 4.54 | 4.45 | 4.59 | 4.4008 | 150,060 |
| 2021-05-24 | 4.66 | 4.54 | 4.66 | 4.5261 | 96,415 |
| 2021-05-21 | 4.62 | 4.64 | 4.74 | 4.54 | 160,952 |
| 2021-05-20 | 4.51 | 4.54 | 4.64 | 4.46 | 85,991 |
| 2021-05-19 | 4.56 | 4.53 | 4.65 | 4.5 | 72,150 |
| 2021-05-18 | 4.52 | 4.59 | 4.7 | 4.5 | 123,394 |
News, Short Squeeze, Breakout and More Instantly...
-
Integrated solution incorporates testing protocols and real-time test results to help ensure safer, healthier campuses, healthcare facilities and other venues Biocept (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products and services, and CLEARED4, a ma...
-
Biocept, Inc. (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products and services, announces that Michael Nall, President and CEO, will present at the LD Micro Virtual Invitational XI Conference on June 9, 2021 at 3:00 p.m. Eastern time (12:00 p.m. Pacific time)...
-
Revenues of $17.8 million were driven by RT-PCR COVID-19 testing Initiated full commercial launch of CNSide™ cerebrospinal fluid assay for diagnosing and managing patients with metastatic cancer involving the central nervous system Received approximately 390,0...